Eloxx Pharmaceuticals (Eloxx Pharmaceuticals) EPS (Diluted) : $-9.07 (TTM As of Sep. 2023)

View and export this data going back to 1998. Start your Free Trial

What is Eloxx Pharmaceuticals EPS (Diluted)?

Eloxx Pharmaceuticals's Earnings per Share (Diluted) for the three months ended in Sep. 2023 was $-1.31. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was $-9.07.

Eloxx Pharmaceuticals's EPS (Basic) for the three months ended in Sep. 2023 was $-1.31. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2023 was $-9.07.

Eloxx Pharmaceuticals's EPS without NRI for the three months ended in Sep. 2023 was $-1.49. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2023 was $-9.07.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Eloxx Pharmaceuticals EPS (Diluted) Historical Data

The historical data trend for Eloxx Pharmaceuticals's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eloxx Pharmaceuticals EPS (Diluted) Chart

Eloxx Pharmaceuticals Annual Data

Trend

Jun13

Jun14

Jun15

Jun16

Jun17

Dec18

Dec19

Dec20

Dec21

Dec22

EPS (Diluted)

Get a 7-Day Free Trial

-58.00

-53.60

-34.40

-38.15

-16.65

Eloxx Pharmaceuticals Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
EPS (Diluted)	Get a 7-Day Free Trial															-3.47	-2.92	-2.88	-1.96	-1.31

Competitive Comparison of Eloxx Pharmaceuticals's EPS (Diluted)

For the Biotechnology subindustry, Eloxx Pharmaceuticals's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Eloxx Pharmaceuticals's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Eloxx Pharmaceuticals's PE Ratio distribution charts can be found below:

* The bar in red indicates where Eloxx Pharmaceuticals's PE Ratio falls into.

Eloxx Pharmaceuticals EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Eloxx Pharmaceuticals's Diluted EPS for the fiscal year that ended in Dec. 2022 is calculated as

Diluted EPS (A: Dec. 2022 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-36.065	-	0)	/	2.166
	=	-16.65

Eloxx Pharmaceuticals's Diluted EPS for the quarter that ended in Sep. 2023 is calculated as

Diluted EPS (Q: Sep. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-3.592	-	0)	/	2.748
	=	-1.31

EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.07

Eloxx Pharmaceuticals (OTCPK:ELOX) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Eloxx Pharmaceuticals EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Eloxx Pharmaceuticals's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

Eloxx Pharmaceuticals (Eloxx Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eloxx Pharmaceuticals Inc (OTCPK:ELOX) » Definitions » EPS (Diluted)

Comparable Companies

Traded in Other Exchanges

N/A

Address

480 Arsenal Way, Watertown, MA, USA, 02472

Website

https://www.eloxxpharma.com

Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in the science of ribosome modulation, leveraging both its ZM chemistry technology platform and its library of novel aminoglycosides to develop novel oral small molecule Ribosome Modulating Agents (RMAs) and Eukaryotic Ribosome Selective Glycosides (ERSGs), for the treatment of rare and ultra-rare genetic diseases where patients have point nonsense genetic mutations that result in premature stop codons and less than full-length proteins. The ELX-02, the company's investigational drug product candidate, is a small molecule designed to restore the production of full-length functional proteins.

Executives

Sumit Aggarwal	director, officer: PRESIDENT AND CEO	480 ARSENAL WAY, WATERTOWN MA 02472
Vijay Modur	officer: HEAD OF R&D	C/O ELOXX PHARMACEUTICALS, INC., 950 WINTER ST., WALTHAM MA 02451
Lindsay Androski	director	C/O ELOXX PHARMACEUTICALS, INC., 480 ARSENAL WAY, WATERTOWN MA 02472
Gadi Veinrib	director	12 MIKHA'EL NE'EMAN ST, TEL AVIV-YAFO L3 6958101
Steven D Rubin	director	OPKO HEALTH, INC., 4400 BISCAYNE BLVD., MIAMI FL 33137
Jasbir Seehra	director	C/O ELOXX PHARMACEUTICALS, INC., 950 WINTER STREET, WALTHAM MA 02451
Zafrira Avnur	director	210 ALLANDALE ST #1B, CHESTNUT HILL MA 02467
Alan Edmund Walts	director	197 8TH STREET, APARTMENT 804, CHARLESTOWN MA 02129
Daniel E. Geffken	officer: Chief Financial Officer	DAMONMILL SQUARE, SUITE 6A, CONCORD MA 01742
Pontifax Iv Gp L.p.	10 percent owner	14 SHENKAR STREET, BEIT OFEK, HERZLIYA PITUACH L3 46140
Pontifax Management 4 G.p. (2015) Ltd.	10 percent owner	14 SHENKAR STREET, BEIT OFEK, HERZLIYA PITUACH L3 46140
Pontifax (israel) Iv, L.p.	10 percent owner	14 SHENKAR STREET, BEIT OFEK, HERZLIYA PITUACH L3 46140
Pontifax (china) Iv L.p.	10 percent owner	14 SHENKAR STREET, BEIT OFEK, HERZLIYA PITUACH L3 46140
Pontifax (cayman) Iv L.p.	10 percent owner	4 SHENKAR STREET, BEIT OFEK, HERZLIYA PITUACH L3 46140
Ran Nussbaum	director	C/O KITE PHARMA, INC., 2225 COLORADO AVENUE, SANTA MONICA CA 90404